within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB17_SampeginterferonBeta1a;

model SampeginterferonBeta1a
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 7.777777777777777e-08,
    adminDuration = 600,
    adminMass = 125 / 1000000,
    adminCount = 1,
    Vd = 0.008,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>SampeginterferonBeta1a</td></tr><tr><td>ATC code:</td><td>L03AB17</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>125</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.004</td><td>liter/hour/kilogram</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Sampeginterferon beta-1a is a long-acting, pegylated form of interferon beta-1a, designed for the treatment of relapsing forms of multiple sclerosis (MS). Pegylation provides prolonged half-life, allowing for less frequent dosing compared to non-pegylated forms. Sampeginterferon beta-1a has been under clinical investigation for MS, but as of 2024, no product with this specific name is approved or marketed.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a pegylated interferon beta-1a formulation, based on models and properties reported for peginterferon beta-1a in healthy volunteers and MS patients.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L03AB17 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end SampeginterferonBeta1a;
